Work

Outcomes in patients with B-cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin stratified by body mass index.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.6541

Authors: Wendy Stock, Ryan Daniel Cassaday, Daniel J. DeAngelo, Anjali S. Advani, Nicola Gökbuget, Jose-Maria Ribera-Santasusana, Wei Jiang, Susana Pulido, Erik Vandendries, Elias Jabbour, Hagop M. Kantarjian

Institutions: University of Chicago, University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Cleveland Clinic, University Hospital Frankfurt, Institut Català d'Oncologia, Pfizer (United States), Pfizer (Spain), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4410809358

Cites:

Cited by: 1

Related to: 10